Gilead’s RA Hopeful Filgotinib Hit By Complete Response Letter
FDA Concerned About High Dose And Testicular Side Effects
Executive Summary
Complete Response Letter is a major setback for Gilead and its partner Galapagos.
You may also be interested in...
Galapagos Loses Potential Ticket To America As Crohns Trial Flops
The company reported the Phase III DIVERSITY trial of Jyseleca did not meet its primary endpoint in Crohn’s disease, closing another path to the US market.
EVOQ Partners With Gilead On NanoDisc Approach To RA, Lupus
Michigan biotech follows 2021 collaboration in autoimmune disease with Amgen with its second tie-up, teaming up with Gilead in rheumatoid arthritis and systemic lupus erythematosus.
MANTA Brings Glimmer Of Good News To Galapagos
After a difficult spell for the Belgian biotech, positive interim data from two key studies looking at testicular toxicity concerns over filgotinib suggest a pathway for potential future US approval of the Gilead-partnered JAK inhibitor for IBD.